Finanzen von Intelligent Bio Solutions Inc (INBS)INBSIntelligent Bio Solutions Inc

Intelligent Bio Solutions Inc (INBS) generates its revenue primarily from Commercially available Intelligent Fingerprinting Products , which accounts for 93.6% of total sales, equivalent to $789.64K. Understanding this concentration is critical for investors evaluating how INBS navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, Intelligent Bio Solutions Inc maintains a gross margin of 21.68%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -345.99%, while the net margin is -341.89%. These profitability ratios, combined with a Return on Equity (ROE) of -292.25%, provide a clear picture of how effectively INBS converts its operational activities into shareholder value.

In the context of the broader market, INBS competes directly with industry leaders such as BMGL and TNON. With a market capitalization of $7.14M, it holds a significant position in the sector. When comparing efficiency, INBS's gross margin of 21.68% stands against BMGL's 100.00% and TNON's 68.53%. Such benchmarking helps identify whether Intelligent Bio Solutions Inc is trading at a premium or discount relative to its financial performance.

The company has shown fluctuating revenue, with Q1 2026 revenue at $1,111,797, but continues to report significant net income losses, with Q4 2026 net income at -$3,907,667. Gross margin has improved to 21.68% in Q4 2026, up from negative margins in previous quarters, indicating some operational improvements.